Monitor vote outcome on the option repricing proposal. If passed, it may improve employee retention but could cause modest dilution. No immediate trading catalyst.
CHRS drugs
CHRS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $1.75entry
- T+1 · 6mo ago +0.57%α +0.90% · $1.76
- T+5 · 6mo ago −2.29%α −3.42% · $1.71
- T+20 · 6mo ago −16.00%α −18.78% · $1.47
- T+60 · 4mo ago −19.43%α −21.49% · $1.41
Price Chart
How similar events traded
Executive Summary
Coherus Oncology filed definitive additional proxy materials (DEFA14A) reminding employees to vote at the May 27, 2026 annual meeting. The key proposal is a repricing of employee stock options with strike prices at or above $5 down to the closing price on the meeting date. The filing is a routine solicitation with no material financial impact.
Key Financial Metrics
Key Facts
- Annual meeting scheduled for May 27, 2026 at 1:30pm PST.
- Proposal to reprice employee stock options with strike prices ≥$5 to the closing price on meeting date.
- Passage requires majority of votes cast 'FOR'.
- Proxy solicitor contact provided: Christopher Rice at (203) 561-6945.
- Email sent by Chief Human Resources Officer Rebecca Sunshine.
Financial Impact
Not specified
Risk Factors
- Proposal may fail if not enough votes are cast in favor.
- Potential dilution from repriced options if exercised.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-055695 |
| Document: 0001104659-26-055695-index-headers.html | 0001104659-26-055695 |
| Document: 0001104659-26-055695-index.html | 0001104659-26-055695 |
| Document: 0001104659-26-055695.txt | 0001104659-26-055695 |
Track record
15 reports on CHRS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.97% at T+5 after the Feb 28, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Bearish 4/10 Entry $0.5250 Now $0.5060 +3.62% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $0.6409 Now $0.5060 −21.05% settles Feb 8
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $0.8984 Now $0.5060 −43.68% settles Jan 27
- Oct 14, 20264w ago Press Release Neutral 4/10 Entry $1.07 Now $0.5060 −52.71% settles Jan 12
- Aug 17, 202613w ago Press Release Neutral 4/10 Entry $1.34 to $0.6409 Now $0.5060 −62.24% ▼ −52.17% −50.13% vs SPY
- Jul 22, 202616w ago Press Release Neutral 1/10 Entry $1.43 to $1.07 Now $0.5060 −64.62% ▼ −25.17% −28.44% vs SPY
- Jun 15, 202622w ago 8-K Neutral 3/10 Entry $1.38 to $1.34 Now $0.5060 −63.33% ▼ −2.90% −3.90% vs SPY
- Jun 12, 202622w ago Institutional Cluster Bearish 4/10 Entry $1.40 to $1.37 Now $0.5060 +63.86% ▲ +2.14% +5.41% vs SPY
- May 28, 202624w ago DEFA14A Neutral 4/10 Entry $1.65 to $1.42 Now $0.5060 −69.33% ▼ −13.94% −15.67% vs SPY
- May 11, 202627w ago Press Release Mixed 6/10 Entry $1.71 to $1.27 Now $0.5060 −70.41% ▼ −26.02% −30.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers